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Brief Communication
Comparison of Antidepressant Efficacy-related 
SNPs Among Taiwanese and Four Populations in 
the HapMap Database
Mei-Hung Chi,1 Sheng-Yu Lee,1 Hui-Hua Chang,3 Yen-Kuang Yang,1,2 Eugene Lin,4 Po-See Chen1,2*
The genetic influence of single nucleotide polymorphisms (SNPs) on antidepressant efficacy has been pre-
viously demonstrated. To evaluate whether there are ethnic differences, we compared the allele frequencies
of antidepressant efficacy-related SNPs between the Taiwanese population and four other populations in
the HapMap database. We recruited 198 Taiwanese major depression patients and 106 Taiwanese controls.
A panel of possible relevant SNPs (in brain-derived neurotrophic factor, 5-hydroxytryptamine receptor 2A,
interleukin 1 beta, and G-protein beta 3 subunit genes) was selected for comparisons of allele frequencies
using the χ2 test. Our results suggested no difference between Taiwanese patients and controls, but there
were significant differences among Taiwanese controls and the other four ethnic groups in brain-derived
neurotrophic factor, 5-hydroxytryptamine receptor 2A, interleukin 1 beta and G-protein beta 3 subunit
genes. We conclude that there are ethnic differences in the allele frequencies of antidepressant efficacy-
related SNPs, and that the degree of variations is consistent with geographic distances. Further investigation
is required to verify the attribution of genetic differences to ethnic-specific antidepressant responses.
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Depressive disorder is a common, severe, and
often life-threatening illness that causes disabil-
ity. Although multiple pharmacological treatments
for depression are available, the heterogeneity of
clinical responses to antidepressants among in-
dividuals makes it difficult to predict an individ-
ual’s response to a specific treatment.
Recent pharmacogenetic studies suggest that the
efficacy of antidepressants is influenced by the com-
bined effects of a number of genetic variants.1–4
Genes in the monoaminergic system, the neuro-
trophic and neuroprotective processes, and stress
hormone systems that are involved in the patho-
genesis of major depression have all been reported
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to be associated with the antidepressant response.
Previous studies have indicated that single nu-
cleotide polymorphisms (SNPs) within brain-
derived neurotrophic factor (BDNF),5 G-protein
beta 3 subunit (GNB3),6,7 5-hydroxytryptamine
receptor 2A (HTR2A),8,9 and interleukin 1 beta
(IL1B) genes10,11 are strongly associated with the
treatment efficacy of antidepressants. Our previous
report also showed that these variants are associ-
ated with an antidepressant treatment response
in the Taiwanese population.12 Other relevant
studies from the Taiwanese population have also
reported this association.10
Previous studies have suggested that antide-
pressant responsiveness may be variable among
different ethnic groups.13 Variations in allele fre-
quencies may influence the antidepressant re-
sponse in different ethnic groups, although the
exact SNP allele frequencies of different ethnic
groups and their effects need further investiga-
tion.13,14 With the release of the HapMap data-
base, which was constructed for the entire human
genome based on high-throughput SNPs, the de-
tection of specific DNA sequence-affecting re-
sponses to drugs is now possible.15 Since relevant
data in the Taiwanese population is currently
sparse, the purpose of this study was to compare
the allele frequencies for SNPs of the BDNF,
HTR2A, IL1B and GNB3 genes between the TWN
population and a Taiwanese patient group, and
four populations of the HapMat database.16
Subjects and Methods
Subjects
Our study population consisted of Taiwanese con-
trols (TWN-C) and Taiwanese patients (TWN-P).
TWN-C were recruited through advertisements.
One hundred six participants (35 men and 71
women) were interviewed by experienced psy-
chiatrists using the Chinese version of the Mini
International Neuropsychiatric Interview (MINI).17
Their mean age (±SD) was 34 ± 12.7 years old.
For the TWN-P group, 198 patients who fulfilled
the DSM-IV criteria of major depression were 
recruited from the outpatient psychiatric clinic at
the National Cheng-Kung University Hospital in
Tainan, Taiwan. The patients’ mean age was 40.7±
14.2 years old. There was no significant difference
in the mean age between TWN-P and TWN-C
(p = 0.059). The mean Hamilton Rating Scale for
Depression (HAM-D, with 21 items version) was
23.4 ± 5.8 years (range 15–40 years) before treat-
ment (baseline). Exclusion criteria for all sub-
jects included the following: (1) a concomitant
major psychiatric illness; (2) active alcohol or
drug dependence; and (3) primary neurological
illness, including dementia. The study protocol
was approved by the Ethics Committee for Human
Research at National Cheng Kung University
Medical Center. Informed consent was obtained
from each subject.
Identification of SNPs
Polymorphisms of the candidate genes included
BDNF (rs6265), HTR2A (rs6313), IL1B (rs16944),
and GNB3 (rs5443). These SNPs were selected
since they are relevant to antidepressant efficacy
according to previous studies.5,6,8–10 Primers for
genotyping were designed based on the reference
sequence NT_024897.5 using either the Primer 3
program18 or OLIGO 6 Primer Analysis Software
(Molecular Biology Insights, Inc., Cascade, CO,
USA). All SNPs were genotyped by fluorescent-
based methods using the SNaPshot Multiplex Kit
(Applied Biosystems, Foster City, CA, USA). Melting
curve analysis was executed by a LightCycler instru-
ment (Roche Molecular Biochemicals, Penzberg,
Germany).
Statistical analysis
We compared the common SNPs of (1) the Han
Chinese in Beijing (CHB), (2) USA residents with
European ancestry (CEU), (3) Japanese in Tokyo
(JPT), and (4) Yoruba in Ibadan (YRI) from the
HapMap database with those of the Taiwanese
population.15 Comparison of allele frequencies
between the TWN-C and TWN-P groups and each
of the four populations of the HapMap database
was performed using the χ2 test. A p value of less
than 0.05 was regarded as statistically significant in
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all cases. We analyzed the data using the Statistical
Package for Social Sciences (SPSS 12, SPSS Inc,
Chicago, Illinois, USA).
Results
The allele frequencies among the Taiwanese subjects
and CHB, CEU, JPT, and YRI from the HapMap
database are listed in Table 1. There was no signifi-
cant difference in the two sets of allele frequencies
between the TWN-P and TWN-C populations in the
candidate genes. The allele frequency of SNPs in the
BDNF, HTR2A, and GNB3 genes between TWN-C
and CHB, JPT, CEU and YRI was significantly dif-
ferent. We also found a significant difference in the
allele frequency of SNPs in the IL1B gene between
TWN-C and YRI only (p = 0.048) (Table 2).
Discussion
Our study focused on the four SNPs that have
been proven to be essential in determining an
antidepressant response and have susceptibility
to major depression. Our results showed that 
the allele frequencies of the four SNPs were not 
significantly different between the TWN-P and
TWN-C groups. This suggests that these four SNPs
might not contribute to the susceptibility of
major depression in the Taiwanese population.
However, the allele frequencies of the four SNPs
were significantly different between the Taiwanese
population and four other populations in the
HapMap database. Further clinical trials of eth-
nic groups are required to test whether these 
differences would lead to a different treatment
response.
Table 1. The allele frequencies of Taiwanese patients, controls and the other four populations
Genes/SNPs TWN-P TWN-C CHB CEU JPT YRI
BDNF A: 0.466 A: 0.491 A: 0.631 A: 0.175 A: 0.337 A: 0
G: 0.534 G: 0.509 G: 0.369 G: 0.825 G: 0.663 G: 1
GNB3 T: 0.584 T: 0.602 T: 0.344 T: 0.388 T: 0.398 T: 0.907
C: 0.416 C:0.398 C: 0.656 C: 0.612 C: 0.602 C: 0.093
HTR2A T: 0.628 T: 0.637 T: 0.477 T: 0.45 T: 0.5 T: 0.35
C: 0.372 C: 0.363 C: 0.523 C: 0.55 C: 0.5 C: 0.65
IL1B A: 0.420 A: 0.429 A: 0.477 A: 0.345 A: 0.444 A: 0.566
G: 0.580 G: 0.571 G: 0.523 G: 0.655 G: 0.556 G: 0.434
TWN-P = Taiwanese patients; TWN-C = Taiwanese controls; CHB = Han Chinese in Beijing; CEU = USA residents with European ancestry;
JPT = Japanese in Tokyo; YRI = Yoruba in Ibadan; SNPs = single nucleotide polymorphisms; BDNF = brain-derived neurotrophic factor;
GNB3 = and G-protein beta 3 subunit; HTR2A = 5-hydroxytryptamine receptor 2A; IL1B = interleukin 1 beta.
Table 2. The p values of χ2 tests between different populations
Genes/ TWN-P vs. TWN-C vs. TWN-C vs. TWN-C vs. TWN-C vs.
SNPs TWN-C JPT CHB CEU YRI
BDNF 0.777 0.031 0.046 2.754*10−6 2.417*10−12
GNB3 0.774 0.005 2.299*10−4 0.003 3.456*10−7
HTR2A 0.883 0.046 0.023 0.007 4.106*10−5
IL1B 0.886 0.887 0.478 0.225 0.048
*Statistically significance. TWN-P=Taiwanese patients; TWN-C=Taiwanese controls; CHB=Han Chinese in Beijing; CEU=USA residents
with European ancestry; JPT = Japanese in Tokyo; YRI = Yoruba in Ibadan; SNPs = single nucleotide polymorphisms; BDNF = brain-derived
neurotrophic factor; GNB3 = and G-protein beta 3 subunit; HTR2A = 5-hydroxytryptamine receptor 2A; IL1B = interleukin 1 beta.
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Interestingly, we found an association between
geographic distance and the degree of genetic vari-
ations of the Taiwanese, CHB, JPT, CEU and YRI
populations. YRI showed the greatest genetic dif-
ference compared with the TWN-C. These results
suggest the possibility of a higher degree of simi-
larity in antidepressant response in ethnic groups
with shorter geographic distances between them.
A larger-scale regional epidemiologic investi-
gation targeted at comparing antidepressant re-
sponses across ethnicities is needed to verify this
hypothesis.
SNPs of the HapMap database that show the
greatest diversity may have evolutional significance
and deserve further investigation.19 Identifying the
variations among ethnic groups and individuals
may lead to the presentation of different symptom
profiles as well as treatment responses of major
depressive disorders.14,20 The results of the current
study further support the need for pharmacoge-
netic studies aimed at identifying the effect of 
genetic polymorphisms on the action of antide-
pressants and designing effective individualized
therapies for major depression.13 Pharmacogenetic
knowledge regarding the SNPs associated with de-
pressive disorders and treatment responses would
be invaluable for stratifying patient eligibility for
a drug to avoid adverse reactions and for raising
pharmacoeconomic efficacy.21
The main limitation of the present study is that
the relatively small sample size may not be repre-
sentative of the Taiwanese population. We em-
ployed statistical power calculations for allele
frequencies between TWN-C and the other four
populations. Given a 5% level of significance and
a set beta of 0.2, the power was 0.8. Estimates of
the sample sizes for BDNF, GNB3, HTR2A, and
IL1B were 81, 46, 99, and 103, respectively. Further-
more, we only compared genetic polymorphisms
of normal populations to match the sample 
selection criteria from the HapMap database.13
Comparison of patient populations of different
ethnicities could provide more direct evidence of
genetic effects on antidepressant responses. If a
similarity of antidepressant efficacy in ethnic
groups with shorter geographic distances could
also be found, and genetic variation is proven to
be associated with antidepressant efficacy, a more
effective antidepressant treatment could be cho-
sen according to ethnic and genetic factors.
In conclusion, there are significant differences
in the allele frequencies of SNPs in antidepressant
response-related genes across ethnicities, and the
degree of genetic variations is consistent with the
geographic distances among groups. Further in-
vestigation is needed to verify whether ethnic-
specific differences in the antidepressant treatment
response are attributable to genetic differences.
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